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Intensive breast screening in BRCA2
mutation carriers is associated with
reduced breast cancer specific and all
cause mortality
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Abstract
Background: The addition of annual MRI screening to mammography has heightened optimism that intensive
screening along with improved treatments may substantially improve life expectancy of women at high risk
of breast cancer. However, survival data from BRCA2 mutation carriers undergoing intensive combined breast
screening are scarce.
Methods: We have collated the results of screening with either annual mammography or mammography
with MRI in female BRCA2 mutation carriers in Manchester and Oslo and use a Manchester control group of
BRCA2 mutation carriers who had their first breast cancer diagnosed without intensive screening.
Results: Eighty-seven BRCA2 mutation carriers had undergone combined (n = 34) or mammography (n = 53)
screening compared to 274 without such intensive screening. Ten year breast cancer specific survival was
100 % in the combined group (95 % CI 82.5–100 %) and 85.5 % (95 % CI 72.6–98.4 %) in the mammography
group compared to 74.6 % (95 % CI 66.6–82.6 %) in the control group. Better survival was driven by lymph
node status (negative in 67 % of screened vs 39 % of unscreened women; p < 0.001) and a significantly
greater proportion of intensively screened women had invasive breast cancers <2 cm at diagnosis (74.6 % vs
50.4 %; p = 0.002).
Conclusion: Intensive combined breast cancer screening with annual MRI and mammography appears to
improve survival from breast cancer in BRCA2 mutation carriers. Data from larger groups are required to confirm
the effectiveness of combined screening in BRCA2 carriers.
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Background
High penetrance inherited breast cancer is mainly
caused by pathogenic mutations in the BRCA1 and
BRCA2 genes. When these genes were identified, it soon
became clear that breast cancer in women with
pathogenic mutations in BRCA1 had worse prognostic
features compared with women carrying pathogenic
BRCA2 mutations who have tumours more reflective of
breast cancer in the general population although still
with a marginally increased level of high grade tumours
[1–3]. Whilst strongly associated with triple negative
breast cancer, most young patients with this breast can-
cer subtype do not carry pathogenic BRCA1 mutations
[4]. Additionally the vast majority of older women with
familial breast cancers with good prognostic markers
and good prognosis do not carry pathogenic BRCA2 mu-
tations [5]. The majority of families with smaller
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aggregations of breast cancer do not yet have demon-
strable underlying genetic defects and the majority of car-
riers of pathogenic mutations in BRCA1 and BRCA2 do
not have strong aggregation of breast cancer in their fam-
ilies [6]. Although caused by genes involved in homolo-
gous DNA repair, breast cancers caused by BRCA1 and
BRCA2 mutations appear to be rather different diseases.
Initially, all carriers of pathogenic BRCA1/2 mutations
were advised to be mammographically screened from a
young age [1]. However the prognosis for BRCA1-associ-
ated breast cancer remained serious despite early
mammography surveillance [7]. Consequently. Magnetic
Resonance Imaging (MRI) was advised to improve early
diagnosis, and with resultant downstaging of tumours at
diagnosis being demonstrated [8–12]. This lead to hope
for improved survival [13] based on projection of observa-
tions of tumours in patients without demonstrated
BRCA1 mutations, assuming that their biology and re-
sponse to treatment were similar. A validation of this hope
based on empirical observed outcome of MRI screening in
BRCA1 carriers is, however, still lacking - besides a few re-
ports indicating that it may not be the case [14, 15].
The prevalence of pathogenic BRCA2 mutations in
breast cancer cases is, however, less than for BRCA1 in
most of Western Europe and North America, which
may be why reports on the outcome of early diagnosis
with MRI in carriers of pathogenic BRCA2 mutations
are even sparser. This is presumed to be why many re-
ports on the effects of early diagnosis on inherited breast
cancer have combined BRCA1 and BRCA2 mutation
carriers together to provide sufficient enough cases to
arrive at a significant conclusion. However, by combin-
ing two biologically different groups of tumours, the
average may not be true for individual patients. We pre-
viously reported that the outcome of early diagnosis with
mammography and MRI for carriers of pathogenic
BRCA1 mutations [16] was not as good as was hoped
for. We now report that the observed outcome of mam-
mography and MRI in the carriers of pathogenic BRCA2
mutations was better: the outcome in screened women
carrying a pathogenic BRCA2 variant was significantly
superior to non-screened controls.
Material and methods
Randomised control trials of screening in BRCA2 muta-
tion carriers are not feasible given the evidence that
MRI screening has been shown to be effective at early
detection with small more node negative cancers identi-
fied [8–12] and offering less than indicated in the
current guidelines was considered unacceptable. We
therefore assessed our prospective screening in BRCA2
mutation carriers compared with an unscreened prag-
matic control group. Women unaffected by breast can-
cer undergoing either annual mammography or
combined annual mammography and MRI breast
screening with pathogenic mutations in the BRCA2 gene
at time of breast cancer diagnosis or who later became
identified from post-diagnosis testing were eligible for
this study. Screening took place at the Genesis Preven-
tion Centre in Manchester and in the regional hospitals
in Norway where Oslo University Hospital served the
majority of the mutation carriers between 1990 and
2014. Known BRCA2 mutation carriers aged 30–50
years were offered annual mammography from 1996
(there are some prospective data with mammography
from 1990 in women later found to be BRCA2 mutation
carriers) with the addition of MRI from 1997 (aged 30–
50 years) with 12–18 monthly mammography after age
50 in the Manchester series. In the Norwegian series car-
riers were offered annual mammography combined with
MRI from 25 to 70 years of age from 2001 onwards. Be-
fore MRI was available, and in cases where the BRCA2
mutation was not detected until later, all BRCA2 muta-
tion carriers were subject to annual mammography with-
out MRI in both Manchester and Norway [7]. All
women were followed prospectively from breast cancer
diagnosis. In Manchester age at last follow up or death
was determined from hospital notes or the North West
Cancer Intelligence Service (NWCIS) in October 2012
and NHS tracing in June 2014. Cause of death was
established from NWCIS. In Norway, the outpatient
genetic clinic in Oslo referred all patients for each single
screening examination. Resultant screening reports and
other outcomes, including follow-up after cancer diag-
nosis and causes of death were noted in the medical
files. All prospectively detected cases had blood samples
stored to be analysed later with updated methods if no
mutation was detected initially. All women with pro-
spective breast cancer were offered full BRCA1/2 testing
with sequencing and Multiple Ligation dependant Probe
Amplification (MLPA). In Manchester, 22/302 (7.3 %)
prospective breast cancers had not been tested, but there
were only two deaths in the non-tested group. None of
the Norwegian women with breast cancer were untested.
The pragmatic controls were diagnosed between 1996
and 2014 and were obtained from the Manchester Re-
gional Genetic Register for BRCA2. Controls had only
undergone population 3-yearly screening by mammog-
raphy from 50 to 69 years of age or had not undergone
radiological surveillance at all. Mutation testing was car-
ried out after diagnosis, sometimes up to 10-years later.
Follow-up from diagnosis to death or last known date
living was as above. Survival curves were compared by
Kaplan-Meier analysis.
Results
Combining the published series from Manchester and
Oslo increases the number of BRCA2 mutation carriers
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diagnosed with breast cancer in a combined MRI/mam-
mography programme from 20 to 34 when only women
unaffected with breast cancer at entry are included [15,
16]. Similarly, the mammography group was expanded
from 30 to 53 women from the UK report [16] (Table 1).
There were 8 interval cancers in the mammography
alone group and two in the combined group one of
which was a 13 mm node negative invasive cancer found
at risk reducing mastectomy. There were 274 carriers
identified in the comparison group of which 260 had in-
vasive breast cancer. There have been no deaths in the
MRI group. Age at diagnosis ranged from 33 to 74 years
(median 43) and there were 180 years of follow up
(range 0.0-13.1; mean 5.3; median 4.0). In the mam-
mography alone group, age at diagnosis ranged from
28 to 77 years (median 48) and there were 404 years
of follow up (range 0.3–19.4; mean 7.6; median 6.7).
There were six deaths in the mammography group,
five from breast cancer and one from primary lung
cancer. Median date at diagnosis was 04/2006 in the
screened group with first cancer identified in 1993,
although the first MRI detected cancer was in 2000.
The controls were diagnosed aged 22–72 years (me-
dian 46.1) with 1525.one years of follow up (range 0–
16.6; mean 5.56; median 4.7). Median date at diagno-
sis was 04/2003. There were 41 deaths: 37 from
breast cancer, three from ovarian cancer, and one from
heart disease.
Ten-year overall and breast cancer specific survival
was 100 % in the combined group and 85.5 % in the
mammography group and 70.8 % and 74.6 % respectively
in the controls (Table 1; Fig. 1). There were 16 alive
without metastasis in the MRI group with more than 5-
years follow up and nine with more than nine years
follow up. Ten-year survival was 89.8 % in those BRCA2
mutation carriers undergoing any form of intensive
(mammography only or combined) screening compared
with 74.6 % in controls (p = 0.026). Breast cancer specific
survival remained significantly better at 20 years (Fig. 2).
Tumour characteristics are presented in Tables 2 and
3. Pathology was only available for grade on 175/260
(67 %) and for tumour size on 127/260 (49 %) of con-
trols since many were diagnosed in other hospitals in
the UK. However, the dates of diagnosis and whether
they had invasive disease was known from cancer
registration data for all controls. Tumours in the
screened group were more likely to be DCIS: 19/87
(21.8 %) versus 14/274 in the comparison group
(5.1 %) (p < 0.001). Invasive tumours in screened cases
were significantly smaller (p = 0.002) and more likely
to be node negative (Table 3: p = 0.001). The main
driver of mortality appeared to be lymph node status;
there was 83 % 10-year survival in node negative dis-
ease compared to 68 % for those with positive nodes
(p = 0.019). Node negative screened cases did ex-
tremely well with 96 % 10-year survival compared to
72 % for node positive screened cases (p = 0.049). Sur-
prisingly, tumour size and grade did not predict sur-
vival, although this may be confounded by the low
proportion of unscreened women (among whom most
of the deaths occurred) with full pathology data avail-
able. Age also appeared to have no effect in either the
screened or unscreened groups.
BRCA2 status was established on average six years
post breast cancer diagnosis in the controls, with a me-
dian time of 4.7 years. HER2 data was only available on
a small proportion of women from each group as HER2
testing was not fully implemented until 2006.











P value overall survival
compared to unscreened
Unscreened 274 70.8 (62.2 to 79.4) 74.6 (66.6 to 82.6)








Any screening 87 (5 detected on
mammography only
in MRI group and 6
with both modalities)
89.5 (79.5 to 99.5) 0.017 89.5 (79.5 to 99.5) 0.029
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However, only around 7 % of BRCA2 carriers known
in Manchester (12/175) are HER2 positive and only one
of the screened cases was known to be HER2 positive.
Discussion
Although there is evidence for a projected improvement
in survival from annual mammography screening in fa-
milial breast cancer (from those largely at low risk of
BRCA1/2) under 50 years of age [17, 18], this is the first
time that a prospectively observed reasonably large
series of BRCA2 carriers has been shown to have an ap-
parent survival advantage from annual screening. Re-
cently a Dutch group showed no improvement in
survival, based on only two deaths out of 18 BRCA2 re-
lated breast cancers compared to three events in con-
trols [19]. Nonetheless the same group reported that
annual mammography screening beyond 60 years of age
in BRCA1/2 carriers is associated with a marked
Fig. 1 Breast cancer specific survival on Kaplan-Meier analysis for combined MRI and mammography versus no intensive screening
Fig. 2 Kaplan-Meier survival plot for breast cancer specific deaths for those BRCA2 mutation carriers undergoing any intensive screening versus
no additional screening (p = 0.029)
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improvement in tumour stage at diagnosis, with 58 % di-
agnosed at stage two or above with usual two-yearly
screening compared to only 21 % in the annual group
[20]. Additionally, the interval cancer rate was doubled
by extending screening to two years. The data from this
and the present study concur with NICE guidelines in
England and Wales who recommend annual mammog-
raphy for BRCA1/2 carriers until 70 years of age [21].
Although the present study has used a pragmatic
comparison group of BRCA2 carriers not undergoing in-
tensive screening a true matched control series would be
impossible as women who knew they were mutation car-
riers would be very unlikely to not undergo added
surveillance.
The current situation is that no single centre has a
series large enough and well enough constructed and
documented to provide a definitive answer to the
question of whether MRI breast screening improves
Table 2 Tumour and age characteristics in intensively screened and unscreened women
MRI/mammography Mammography No screening Total p value
In situ (n = 33, 79.1 %) Ductal 10 (100) 9 (100) 14 (100) 33 (100) 1.0
Lobular 0 (0) 0 (0) 0 (0) 0 (0)
Invasive breast cancer
(n = 328, 90.9 %)
Type (n = 328) Ductal 24 (96.0) 41 (95.3) 244 (93.8) 309 (94.2)
Lobular 1 (4.0) 1 (2.3) 16 (6.2) 18 (5.5)
Mixed 0 (0) 1 (2.3) 0 (0) 1 (0.3)
Age groups (n = 328) <50 years 17 (68.0) 23 (53.5) 168 (64.6) 208 (63.4) 0.330
> = 50 Years 8 (32.0) 20 (46.5) 92 (35.4) 120 (36.6)
Nodes (n = 148) 0 18 (78.3) 23 (60.5) 34 (39.1) 75 (50.7)
1 2 (8.7) 8 (21.1) 17 (19.5) 27 (18.2)
2–3 1 (4.3) 6 (15.8) 17 (19.5) 24 (16.2)
4–5 0 (0) 1 (2.6) 9 (10.3) 10 (6.8)
6+ 2 (8.7) 0 (0.0) 10 (11.5) 12 (8.1)
Missing 2 5 173 180
Nodes (n = 148) Negative 18 (78.3) 23 (60.5) 34 (39.1) 75 (50.7) 0.001
Positive 5 (21.7) 15 (39.5) 53 (60.9) 73 (49.3)
ER-status (n = 211) Negative 3 (18.8) 11 (27.5) 34 (21.9) 48 (22.7) 0.698
Positive 13 (81.3) 29 (72.5) 121 (78.1) 163 (77.3)
Missing 9 3 105 117
Grade (n = 237) 1 1 (4.3) 4 (10.3) 6 (3.4) 11 (4.6)
2 11 (47.8) 15 (38.5) 63 (36.0) 89 (37.6)
3 11 (47.8) 20 (51.3) 106 (60.6) 137 (57.8)
Missing 2 4 86 91
Grade (n = 237) 1/2 12 (52.2) 19 (48.7) 69 (39.4) 100 (42.2) 0.338
3 11 (47.8) 20 (51.3) 106 (60.6) 137 (57.8)
Censored (n = 328) Alive 25 (100) 38 (88.4) 222 (85.4) 285 (86.9) 0.112
Dead 0 (0.0) 5 (11.6) 38 (14.6) 43 (13.1)
Size (n = 186) <10 9 (42.9) 10 (26.3) 9 (7.1) 28 (15.1)
10 – 19.9 8 (38.1) 17 (44.7) 55 (43.3) 80 (43.0)
20 – 29.9 3 (14.3) 9 (23.7) 36 (28.3) 48 (25.8)
30 – 39.9 0 (0.0) 1 (2.6) 12 (9.4) 13 (7.0)
40 – 49.9 0 (0.0) 1 (2.6) 7 (5.5) 8 (4.3)
> = 50 1 (4.8) 0 (0.0) 8 (6.3) 9 (4.8)
Missing 4 5 133 142
Size (n = 186) <20 17 (81.0) 27 (71.1) 64 (50.4) 108 (58.1) 0.006
> = 20 4 (19.0) 11 (28.9) 63 (49.6) 78 (41.9)
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p value for 2nd category
(e.g. <50 vs 50+)
p value for screened vs no
screening for each category
No screening 260 38 0.871 (0.025) 0.728 (0.043) 0.089
Screened 68 5 0.917 (0.040) 0.863 (0.065)
All (n = 328)
<50 year 208 25 0.895 (0.025) 0.795 (0.040) 0.117
50+ yrs 120 18 0.853 (0.040) 0.647 (0.088)
Screened
<50 year 40 3 0.941 (0.041) 0.869 (0.079) 0.690 0.216
50+ yrs 28 2 0.867 (0.088) 0.867 (0.088) 0.214
No screening
<50 year 168 22 0.883 (0.030) 0.777 (0.045) 0.121
50+ yrs 92 16 0.847 (0.045) 0.570 (0.111)
All (n = 211)
ER neg 48 3 0.913 (0.048) 0.913 (0.048) 0.130
ER pos 163 23 0.909 (0.028) 0.686 (0.064)
Screened
ER neg 14 0 1 1 0.146 0.238
ER pos 42 5 0.862 (0.065) 0.755 (0.116) 0.694
Not screened
ER neg 34 3 0.875 (0.068) 0.875 (0.068) 0.375
ER pos 121 18 0.925 (0.030) 0.665 (0.074)
All (n = 237)
Grade 1/2 100 12 0.892 (0.039) 0.740 (0.076) 0.943
Grade 3 137 18 0.887 (0.032) 0.776 (0.050)
Screened
Grade 1/2 31 2 0.900 (0.067) 0.900 (0.067) 0.980 0.248
Grade 3 31 2 0.920 (0.055) 0.920 (0.055) 0.185
No screening
Grade 1/2 69 10 0.889 (0.047) 0.668 (0.101) 0.958
Grade 3 106 16 0.876 (0.039) 0.729 (0.062)
All (n = 148)
Node neg (0) 75 5 0.958 (0.029) 0.829 (0.076) 0.019
Node pos (1+) 73 14 0.823 (0.054) 0.676 (0.077)
Screened
Node neg (0) 41 1 0.962 (0.038) 0.962 (0.038) 0.049 0.209
Node pos (1+) 20 4 0.821 (0.094) 0.718 (0.127) 0.706
No screening
Node neg (0) 34 4 0.955 (0.044) 0.728 (0.123) 0.164
Node pos (1+) 53 10 0.822 (0.067) 0.667 (0.089)
All (n = 186)
<20 mm 108 14 0.922 (0.029) 0.752 (0.058) 0.884
20 +mm 78 10 0.865 (0.048) 0.778 (0.064)
Evans et al. Hereditary Cancer in Clinical Practice  (2016) 14:8 Page 6 of 8
survival in BRCA2 mutation carriers. This is why
close to all major organisations world-wide addressing
these questions have organised ‘THE BRCA CHAL-
LENGE’ (http://www.humanvariomeproject.org/brca-
challenge.html) which at the 2015 meeting in the
UNESCO centre in Paris called for a broad inter-
national collaboration to provide answers to the un-
answered questions. In this context we report our
findings and encourage others to do the same, so as
to move our knowledge on effects of interventions to
prevent BRCA2-associated breast cancer death from
assumptions to empirical observed effects of interven-
tions. Until the time when more definitive answers
are available female BRCA2 carriers will still require
guidance on whether surveillance with MRI and
mammography offers similar improvements in life ex-
pectancy than can be gained from risk reducing sur-
gery [13, 22].
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